A flurry of federal prosecutorial activity in late 2024, as well as a statement from several institutional stakeholders in a key federal initiative ...

If approved by the judge overseeing the lawsuit, the injunction would allow students to keep attending the schools that DPS ...

TAMPA, Fla. - Mihir Taneja has agreed to pay the United States $2 million to resolve allegations that he violated the False ...

Defense Contractor Executive Pleads Guilty to Bribery Scheme Involving Over $100 Million in Government Contracts ...

Atossa is also announcing the issuance of a new patent on January 21, 2025, U.S. Patent No. 12,201,591, entitled, “Sustained Release Compositions of Endoxifen.” The 31 claims of this new patent are ...

(Z)-endoxifen is currently being studied in five Phase 2 trials: one in healthy women with measurable breast density, one in women diagnosed with ductal carcinoma in situ, and three other studies ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of ...

Christopher Dillard, the special agent in charge of a DoD Defense Criminal ... federal procurement dollars while cheating taxpayers. DCIS is proud to work with our law enforcement partners to ...

the special agent in charge of a DoD Defense Criminal Investigative Service, said the "outcome demonstrates our commitment to aggressively investigate those who enrich themselves with federal ...

Ductal carcinoma in situ is a precursor of breast cancer that is usually treated with surgery, radiation therapy, and estrogen blockade. A new study suggests that watchful waiting might be safe for ...

Study Reveals Short Term Safety of Active Monitoring for Ductal Carcinoma in Situ Dec. 12, 2024 — The first study comparing surgery to active monitoring as treatment for ductal carcinoma in situ ...